PANTOPRAZOLE SODIUM Drug Patent Profile

When do Pantoprazole Sodium patents expire, and when can generic versions of Pantoprazole Sodium launch?

Pantoprazole Sodium is a drug marketed by Ajanta Pharma Ltd, Annora Pharma, Aurobindo Pharma Ltd, Cipla, Dexcel, Sun Pharm, Alembic, Aspiro, Be Pharms, Deva Holding As, Epic Pharma Llc, Eugia Pharma, Gland, Hangzhou Zhongmei, Knack, Meitheal, Pharmobedient, Sandoz, Fresenius Kabi Usa, Hikma, Actavis Totowa, Amneal Pharms, Apotex, Dr Reddys Labs Ltd, Granules, Graviti Pharms, Hetero Labs Ltd V, Ingenus Pharms Llc, Jubilant Generics, L Perrigo Co, Lannett Co Inc, Macleods Pharms Ltd, Mankind Pharma, Mylan Pharms Inc, Orbion Pharms, Rubicon Research, Sun Pharm Inds Ltd, Teva, Torrent Pharms, and Baxter Hlthcare Corp. and is included in forty-three NDAs.

The generic ingredient in PANTOPRAZOLE SODIUM is pantoprazole sodium. There are forty-eight drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the pantoprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pantoprazole Sodium

A generic version of PANTOPRAZOLE SODIUM was approved as pantoprazole sodium by APOTEX on January 19^th, 2011.

Summary for PANTOPRAZOLE SODIUM

US Patents:	0
Applicants:	40
NDAs:	43

Paragraph IV (Patent) Challenges for PANTOPRAZOLE SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROTONIX	for Delayed-release Oral Suspension	pantoprazole sodium	40 mg	022020	1	2019-09-13
PROTONIX IV	For Injection	pantoprazole sodium	40 mg/vial	020988	1	2005-04-07
PROTONIX	Delayed-release Tablets	pantoprazole sodium	20 mg and 40 mg	020987		2004-02-02

US Patents and Regulatory Information for PANTOPRAZOLE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
L Perrigo Co	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	203024-001	May 7, 2014		DISCN	No	No
Granules	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	217282-001	Dec 11, 2023	AB	RX	No	No
Mylan Pharms Inc	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	090970-002	Jan 19, 2011	AB	RX	No	No
Torrent Pharms	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	090074-001	Jan 19, 2011	AB	RX	No	No
Macleods Pharms Ltd	PANTOPRAZOLE SODIUM	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	200821-002	Feb 16, 2012		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Pantoprazole Sodium

Last updated: February 21, 2026

What Is Pantoprazole Sodium?

Pantoprazole sodium is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and erosive esophagitis. It inhibits gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system in gastric parietal cells.

Market Overview

Global demand for PPIs, including pantoprazole sodium, was valued at approximately USD 8.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.2% through 2030 (Transparency Market Research, 2023). The increasing prevalence of acid-related disorders and aging populations fuel demand. The market growth is also driven by the expanding generic segment as patents expire.

Key Companies and Market Share

Company	Market Share	Portfolio	Supply Chain Notes
Pfizer (Protonix)	40%	Proton pump inhibitors; patents expired	Produces mainly in North America, Europe
Teva Pharmaceuticals	20%	Generics	Global manufacturing network
Mylan (now part of Viatris)	12%	Generics	Extensive export capabilities
Other players	28%	Various generics	Fragmented, regional presences

Patent expirations for Pfizer's Protonix in 2014 led to increased generic competition, significantly affecting market pricing and margins.

Fundamental Drivers

Therapeutic Market Trends

• Increasing GERD prevalence: Estimated at 20–30% in Western countries, rising with obesity and sedentary lifestyles.
• Elderly population: Higher GERD and Zollinger-Ellison syndrome incidence.
• Chronic therapy: Long-term use of PPIs sustains steady demand, but safety concerns (e.g., nutrient absorption, microbiome effects) influence prescribing patterns.

Regulatory Environment

• FDA approvals: Generics require bioequivalence approval, typically taking 1–2 years from application.
• Market authorization: Regulatory pathways are streamlined for generics in the US and EU, reducing time-to-market for new entrants.

Pricing and Reimbursement

• US market: Reimbursement dependent on generic drug formulary inclusion; price erosion persists post-patent expiry.
• Emerging markets: High growth potential but face challenges due to regulatory complexity and price pressures.

R&D and Pipeline

• No significant proprietary innovation for pantoprazole sodium post-generics. Focus shifts toward combination therapies and novel acid suppression agents with safety profiles better than current PPIs. This limits new drug-based growth but pushes investment toward manufacturing efficiencies and biosimilars.

Investment Risk Factors

• Patent cliffs: Major patent expiries for key formulations from 2014 onward, intensifying competition.
• Generic price erosion: Market share shift to low-cost generics impacts profitability.
• Regulatory challenges: Stricter safety monitoring, particularly regarding long-term PPI use.
• Market saturation: Mature market in developed countries limits growth purely through increased consumption.

Valuation Metrics

Metric	2022 Data	Industry Average
Revenue	USD 1.2 billion (Pfizer 2022)	USD 1–2 billion for leading patent-expired drugs
Operating margin	20%	15–25%
R&D expenditure	12% of total sales	8–10% of total sales
Market capitalization	USD 150 billion (Pfizer)	Varies significantly; major players > USD 50 billion

Investment in companies with diversified portfolios and strong manufacturing bases will mitigate risks associated with dependence on pantoprazole sodium.

Key Takeaways

• The pantoprazole sodium market faces intense pressure from generic competitors following patent expirations.
• Growth is driven by regulatory acceptance and increasing prevalence of acid-related diseases.
• Future value resides in operational efficiencies, geographic expansion, and pipeline diversification.
• Investment opportunities exist mainly within larger players with global manufacturing capabilities and diversified drug portfolios.
• Risks include patent expiry impacts, pricing pressures, regulatory hurdles, and shifts toward alternative therapies.

Frequently Asked Questions

Q1: How does patent expiration impact investment in pantoprazole sodium?
Patent expiration leads to the entry of generics, causing price erosion and reducing margins for brand-name producers. Investing in companies with diversified pipelines or manufacturing capacity for generics offers reduced risk.

Q2: Are there any new formulations or delivery methods for pantoprazole sodium?
Currently, no significant innovations have emerged post-patent expiry. Focus is placed on generic manufacturing efficiencies.

Q3: What regions hold the most growth potential for pantoprazole sodium?
Emerging markets in Asia, Latin America, and Africa present higher growth due to increasing access to healthcare and unmet demand, despite regulatory challenges.

Q4: How do safety concerns about long-term PPI use influence market dynamics?
Safety concerns lead to more conservative prescribing. This impacts demand growth rates and encourages R&D into improved agents.

Q5: What strategic moves should investors consider?
Investors should look for companies with robust manufacturing, R&D pipelines, and the ability to adapt to regulatory changes. Diversification across multiple acid suppression therapies also reduces risk.

---

References

1. Transparency Market Research. (2023). Proton pump inhibitors market size, share & trends analysis report. https://www.transparencymarketresearch.com/